Insulete Overview

  • Founded
  • 2004
Founded
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Insulete General Information

Description

Developer of a diabetes treatment therapy intended to cure Type I diabetes. The company;s therapy uses gene named Diatagene that is delivered through an intravenous injection that utilizes DNA sequencing, enabling doctors to promote the activation of insulin gene within diabetic patient to help curb Type 1 diabetes.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Primary Industry
Biotechnology
Primary Office
  • 3330 University Avenue
  • Suite 120
  • Madison, WI 53705
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Insulete Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Dec-2016 00000 Completed Out of Business
2. Angel (individual) 10-May-2016 00000 00000 Completed Startup
1. Grant Completed Startup
To view Insulete’s complete valuation and funding history, request access »

Insulete Executive Team (4)

Name Title Board Seat Contact Info
Jay Handy Co-Founder, Board Member & Acting Chief Executive Officer
Hans Sollinger MD Co-Founder, President, Chief Executive Officer & Board Member
Tausif Alam Ph.D Chief Financial Officer, Chief Scientist & Board Member
Jeffrey Rusinow Executive Officer & Chairman
To view Insulete’s complete executive team members history, request access »

Insulete Board Members (3)

Name Representing Role Since
Hans Sollinger MD Insulete Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Jeffrey Rusinow Insulete Executive Officer & Chairman 000 0000
Tausif Alam Ph.D Insulete Chief Financial Officer, Chief Scientist & Board Member 000 0000
To view Insulete’s complete board members history, request access »